论文部分内容阅读
肿瘤转移日渐成为肿瘤治疗的重要靶标。本研究采用肿瘤转移靶向肽(TMT)与脂质材料(PEG-DSPE)偶联获得靶向化合物(TMT-PEG-DSPE),用以构建靶向阿霉素脂质体(TMT-LS-DOX)。结果表明,TMT-LS-DOX呈现出良好的药剂学性质。选用高转移性乳腺癌细胞(MDA-MB-435S和MDA-MB-231)对该转移特异性递送系统进行评价,采用非转移性乳腺癌细胞(MCF-7)作为对照。游离TMT多肽浓度达100μg/mL时仍未显示出细胞毒性。与MCF-7相比,MDA-MB-435S及MDA-MB-231细胞对TMT-LS-DOX摄取增加,并经受体竞争性实验证明该促进作用由TMT介导。因此,TMT修饰的纳米载体可能成为增加化疗药物对高转移性乳腺癌特异性的一种新策略。
Tumor metastasis has increasingly become an important target for cancer treatment. In this study, a targeted compound (TMT-PEG-DSPE) was coupled with a lipid material (PEG-DSPE) using a tumor metastasis targeting peptide (TMT) DOX). The results showed that TMT-LS-DOX showed good pharmacological properties. This metastasis-specific delivery system was evaluated using highly metastatic breast cancer cells (MDA-MB-435S and MDA-MB-231) with non-metastatic breast cancer cells (MCF-7) as a control. Cytotoxicity was still not demonstrated when the free TMT polypeptide concentration reached 100 μg / mL. The uptake of TMT-LS-DOX by MDA-MB-435S and MDA-MB-231 cells was increased compared to MCF-7 and was evidenced by TMT mediated by receptor-competitive experiments. Therefore, TMT-modified nanocarriers may be a new strategy to increase the specificity of chemotherapeutic drugs for highly metastatic breast cancer.